Sameer Jauhar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4252727/publications.pdf

Version: 2024-02-01

111 papers	3,869 citations	218677 26 h-index	138484 58 g-index
• •			J
118 all docs	118 docs citations	118 times ranked	4954 citing authors

#	Article	IF	CITATIONS
1	Cognitive–behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry, 2014, 204, 20-29.	2.8	417
2	The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry, 2017, 22, 666-679.	7.9	347
3	Impaired Glucose Homeostasis in First-Episode Schizophrenia. JAMA Psychiatry, 2017, 74, 261.	11.0	328
4	Schizophrenia. Lancet, The, 2022, 399, 473-486.	13.7	278
5	Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry,the, 2015, 2, 718-725.	7.4	240
6	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. Schizophrenia Bulletin, 2018, 44, 1301-1311.	4.3	187
7	A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA Psychiatry, 2017, 74, 1206.	11.0	178
8	Cognitive Behavioural Therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis. BMC Psychology, 2018, 6, 32.	2.1	130
9	Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: Meta-analysis of absolute prefrontal neuro-metabolic concentrations. European Neuropsychopharmacology, 2015, 25, 1109-1117.	0.7	123
10	Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Molecular Psychiatry, 2019, 24, 1502-1512.	7.9	120
11	The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry,the, 2018, 5, 816-823.	7.4	89
12	Nicotine dependence and illness severity in schizophrenia. British Journal of Psychiatry, 2012, 201, 306-312.	2.8	78
13	Antipsychotic plasma levels in the assessment of poor treatment response inÂschizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 39-46.	4.5	76
14	Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study. Biological Psychiatry, 2019, 85, 368-378.	1.3	72
15	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. JAMA Psychiatry, 2021, 78, 667.	11.0	72
16	A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin, 2021, 47, 1116-1129.	4.3	69
17	Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. International Journal of Bipolar Disorders, 2019, 7, 10.	2.2	55
18	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry, 2019, 85, 79-87.	1.3	54

#	Article	IF	Citations
19	Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans Translational Psychiatry, 2017, 7, e1027-e1027.	4.8	53
20	Brain activations associated with anticipation and delivery of monetary reward: A systematic review and meta-analysis of fMRI studies. PLoS ONE, 2021, 16, e0255292.	2.5	47
21	The case for improved care and provision of treatment for people with first-episode mania. Lancet Psychiatry,the, 2019, 6, 869-876.	7.4	46
22	A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach. Neuropsychopharmacology, 2021, 46, 1122-1132.	5.4	34
23	Genetic variants in or near <i>ADHIB</i> and <i>ADH1C</i> affect susceptibility to alcohol dependence in a British and Irish population. Addiction Biology, 2015, 20, 594-604.	2.6	33
24	CBT for schizophrenia: a critical viewpoint. Psychological Medicine, 2019, 49, 1233-1236.	4.5	33
25	Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531987003.	2.7	32
26	Should we stop using electroconvulsive therapy?. BMJ: British Medical Journal, 2019, 364, k5233.	2.3	31
27	Electroconvulsive therapy for depression: 80 years of progress. British Journal of Psychiatry, 2021, 219, 594-597.	2.8	30
28	Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?. BMC Psychiatry, 2012, 12, 27.	2.6	29
29	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. NPJ Schizophrenia, 2019, 5, 12.	3.6	28
30	Understanding and Predicting Variability in Response to Treatment in Psychotic Disorders: In Vivo Findings. Clinical Pharmacology and Therapeutics, 2019, 105, 1079-1081.	4.7	28
31	NICE guidance on psychological treatments for bipolar disorder: searching for the evidence. Lancet Psychiatry,the, 2016, 3, 386-388.	7.4	26
32	The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. ELife, 2017, 6, .	6.0	26
33	Tobacco smoking is associated with psychotic experiences in the general population of South London. Psychological Medicine, 2018, 48, 123-131.	4.5	23
34	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. Molecular Psychiatry, 2021, 26, 1332-1345.	7.9	23
35	Esketamine for treatment resistant depression. BMJ: British Medical Journal, 2019, 366, l5572.	2.3	22
36	One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials. Journal of Psychopharmacology, 2020, 34, 1074-1078.	4.0	22

#	Article	IF	CITATIONS
37	Pharmaceutical industry interactions of psychiatric trainees from 20 European countries. European Psychiatry, 2015, 30, 284-290.	0.2	19
38	Alcohol-related brain damage: not a silent epidemic. British Journal of Psychiatry, 2009, 194, 287-288.	2.8	18
39	Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25years? Nithsdale schizophrenia survey revisited. Schizophrenia Research, 2013, 146, 349-356.	2.0	18
40	A systematic review and metaâ€analysis of treatments for rapid cycling bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 146, 290-311.	4.5	18
41	Is there a symptomatic distinction between the affective psychoses and schizophrenia? A machine learning approach. Schizophrenia Research, 2018, 202, 241-247.	2.0	17
42	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. Scientific Reports, 2019, 9, 8685.	3.3	17
43	Antidepressants, withdrawal, and addiction; where are we now?. Journal of Psychopharmacology, 2019, 33, 655-659.	4.0	17
44	The war on antidepressants: What we can, and can't conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addictive Behaviors, 2019, 97, 122-125.	3.0	15
45	Equal access for all? Access to medical information for European psychiatric trainees. Psychiatry Research, 2016, 238, 150-152.	3.3	14
46	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. Translational Psychiatry, 2021, 11, 425.	4.8	14
47	Pernicious anaemia presenting as catatonia without signs of anaemia or macrocytosis. British Journal of Psychiatry, 2010, 197, 244-245.	2.8	13
48	Alcohol and cognitive impairment. Advances in Psychiatric Treatment, 2014, 20, 304-313.	0.5	13
49	Early intervention for bipolar disorder – Do current treatment guidelines provide recommendations for the early stages of the disorder?. Journal of Affective Disorders, 2019, 257, 669-677.	4.1	13
50	The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Research - Neuroimaging, 2019, 291, 34-41.	1.8	13
51	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Molecular Psychiatry, 2023, 28, 1995-2006.	7.9	13
52	Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness. Science Advances, 2021, 7, .	10.3	13
53	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1040-1051.	1.5	11
54	Psychiatric and behavioural manifestations of Huntington's disease. Advances in Psychiatric Treatment, 2010, 16, 168-175.	0.5	8

#	Article	IF	Citations
55	The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Human Molecular Genetics, 2018, 27, 3498-3506.	2.9	8
56	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. European Neuropsychopharmacology, 2019, 29, 1333-1342.	0.7	8
57	Early Intervention Services for First Episode of Psychosis in South London and the Maudsley (SLaM): 20 Years of Care and Research for Young People. Frontiers in Psychiatry, 2020, 11, 577110.	2.6	8
58	A critique of narrative reviews of the evidence-base for ECT in depression. Epidemiology and Psychiatric Sciences, 2022, 31, e10.	3.9	7
59	Lack of allelic association between markers at the DRD2 and ANKK1 gene loci with the alcohol-dependence syndrome and criminal activity. Psychiatric Genetics, 2011, 21, 323-324.	1.1	6
60	Cognitive behavioural therapyâ€"a valid alternative to antipsychotics for psychosis?. Lancet Psychiatry,the, 2018, 5, 381-383.	7.4	6
61	Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?. Lancet Psychiatry,the, 2020, 7, 726-728.	7.4	6
62	Methodological Biases in CBT Trialâ€"Commentary: Modular Cognitive-Behavioral Therapy for Affective Symptoms in Young Individuals at Ultra-High Risk of First Episode of Psychosis: Randomized Controlled Trial. Frontiers in Psychiatry, 2020, 11, 394.	2.6	6
63	Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations. European Neuropsychopharmacology, 2021, 47, 130-135.	0.7	6
64	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	2.8	6
65	Lack of robust metaâ€analytic evidence to favour cognitive behavioural therapy for prevention of psychosis. World Psychiatry, 2021, 20, 443-444.	10.4	5
66	What is the evidence for antipsychotic medication and alternative psychosocial interventions for people with acute, non-affective psychosis?. Lancet Psychiatry,the, 2022, , .	7.4	5
67	Young psychiatrists' meetings in Eastern Europe – Networking for the development of psychiatric training, education and service. World Psychiatry, 2011, 10, 239-239.	10.4	4
68	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. Biological Psychiatry, 2016, 80, e19-e20.	1.3	4
69	Psychosocial treatments in bipolar disorder. Lancet Psychiatry,the, 2016, 3, 321.	7.4	3
70	Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry, the, 2019, 6, 560-561.	7.4	3
71	Psychosocial Intervention Without Antipsychotic Medication for Brief Psychotic Episodes?. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
72	Integrating research into the career of a psychiatrist in the past, present and future?. The Psychiatrist, 2010, 34, 37-37.	0.3	2

#	Article	IF	Citations
73	Seroquel XL: add-on treatment for major depressive disorder. The Prescriber, 2011, 22, 23-26.	0.3	2
74	Evidence for genetic susceptibility to the alcohol dependence syndrome from the thiamine transporter 2 gene solute carrier SLC19A3. Psychiatric Genetics, 2014, 24, 122-123.	1.1	2
75	Commentary on a study of the prevalence of mental disorders by Breslau etÂal Journal of Psychiatric Research, 2015, 61, 231-232.	3.1	2
76	Ideology over evidence?. BJPsych Bulletin, 2018, 42, 130-131.	1.1	2
77	F227. The State or Trait Component of Dopamine and Glutamate Dysfunction in the Risk for Psychosis: An in Vivo Multimodal Imaging Study of Individuals With 22q11 Deletion. Biological Psychiatry, 2018, 83, S327.	1.3	2
78	Mindfulnessâ€based cognitive therapy and depression relapseâ€"evaluating evidence through a metaâ€analytic lens may indicate myopia. Acta Psychiatrica Scandinavica, 2021, 143, 3-5.	4.5	2
79	OUP accepted manuscript. Schizophrenia Bulletin, 2021, , .	4.3	2
80	The relationship between glutamate, dopamine, and cortical gray matter: A simultaneous PET-MR study. Molecular Psychiatry, 2022, 27, 3493-3500.	7.9	2
81	Authors' reply. British Journal of Psychiatry, 2014, 204, 490-490.	2.8	1
82	Authors' reply. British Journal of Psychiatry, 2015, 207, 269-270.	2.8	1
83	S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION. Schizophrenia Bulletin, 2018, 44, S395-S395.	4.3	1
84	Back to basics―a UK perspective on "Make lithium great again―Malhi et al. Bipolar Disorders, 2021, 23, 97-98.	1.9	1
85	Interpreting the Findings of a Meta-analysis of Psychosocial Interventions in Bipolar Disorder. JAMA Psychiatry, 2021, 78, 448.	11.0	1
86	Morbidity and mortality associated with electroconvulsive therapy: can we control for confounding?. Lancet Psychiatry,the, 2021, 8, 643-644.	7.4	1
87	Antipsychotics, the heartland of clinical psychopharmacology?. Journal of Psychopharmacology, 2021, 35, 1027-1029.	4.0	1
88	Relapse prevention in schizophrenia. Lancet Psychiatry,the, 2022, 9, e13.	7.4	1
89	New Alzheimer's disease screening test performs well in UK outpatient settings. Evidence-Based Mental Health, 2010, 13, 11-11.	4.5	0
90	How do european psychiatry trainees prescribe when treating depression, and what influences decision-making? (Survey of the European Federation of Psychiatric Trainees Research Group). European Psychiatry, 2011, 26, 1248-1248.	0.2	0

#	Article	IF	Citations
91	Authors' reply. British Journal of Psychiatry, 2014, 205, 160-161.	2.8	0
92	Selective reporting of results in guidelines. British Journal of Psychiatry, 2015, 207, 560-561.	2.8	0
93	Tobacco use and psychosis: missing the risk of bias assessment and other methodological considerations – Authors' reply. Lancet Psychiatry,the, 2015, 2, 865-866.	7.4	0
94	275. Glutamate in Psychosis: In Vivo Evidence of Its Role in Treatment Response and the Potential to Modulate Glutamatergic Function. Biological Psychiatry, 2017, 81, S113.	1,3	0
95	O3.5. TESTING THE DOPAMINE HYPOTHESIS OF PSYCHOSIS USING POSITRON EMISSION TOMOGRAPHIC IMAGING IN FIRST EPISODE BIPOLAR AFFECTIVE DISORDER AND SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S81-S81.	4.3	0
96	F226. The Relationship Between Cortical Glutamate and Striatal Dopamine Function in Psychosis: A Multi-Modal PET and MRS Imaging Study in First Episode Psychosis. Biological Psychiatry, 2018, 83, S326-S327.	1.3	0
97	First episode mania: we should have intervened earlier. Lancet Psychiatry,the, 2019, 6, 807-808.	7.4	0
98	6.3 DOES TOBACCO SMOKING CAUSE PSYCHOSIS?. Schizophrenia Bulletin, 2019, 45, S96-S96.	4.3	0
99	S84. THE EFFECT OF ANTIPSYCHOTICS ON GLUTAMATE LEVELS IN THE ANTERIOR CINGULATE AND CLINICAL RESPONSE MEASURED BY PANSS: A 1H-MRS STUDY IN FIRST-EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2019, 45, S339-S339.	4.3	O
100	O5.6. REMISSION FROM ANTIPSYCHOTIC TREATMENT IN FIRST EPISODE PSYCHOSIS RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS. Schizophrenia Bulletin, 2019, 45, S175-S175.	4.3	0
101	S172. GLUTAMATE RELATED CONNECTIVITY DISTURBANCES OF THE SALIENCE AND DEFAULT MODE NETWORKS IN PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S102-S103.	4.3	0
102	M18. REDUCED CORTICAL CEREBRAL BLOOD FLOW IN FIRST EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2020, 46, S140-S140.	4.3	0
103	Changing the clinical landscape for treatment of bipolar disorder—To be (cautiously) welcomed. Bipolar Disorders, 2020, 22, 636-637.	1.9	0
104	Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder., 2021,, 236-247.		0
105	â€~Melancholy can be overwhelmed only by melancholy.' Robert Burton, Anatomy of Melancholy. International Review of Psychiatry, 2021, 33, 205-206.	2.8	0
106	M149. THE TOPOGRAPHY OF STRIATAL DOPAMINE AND SYMPTOMS IN PSYCHOSIS: AN INTEGRATIVE PET AND MRI STUDY. Schizophrenia Bulletin, 2020, 46, S192-S192.	4.3	0
107	Weighing up scientific evidence requires balance, not opinion. British Journal of Psychiatry, 2021, 219, 619-619.	2.8	0
108	Authors' reply. British Journal of Psychiatry, 2013, 202, 75.	2.8	0

SAMEER JAUHAR

#	Article	IF	CITATIONS
109	Bench, bedside, and balance. Journal of Psychopharmacology, 2022, 36, 129-130.	4.0	0
110	ECT is evidence-based – a commentary on depression: why drugs and electricity are not the answer. Psychological Medicine, 2022, 52, 1416-1418.	4.5	0
111	Unbalanced appraisal of psychosocial versus antipsychotic literature – Authors' reply. Lancet Psychiatry,the, 2022, 9, 541.	7.4	O